AEON Biopharma
AEON
24 hedge funds and large institutions have $2.8M invested in AEON Biopharma in 2026 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
68% more capital invested
Capital invested by funds: $1.67M → $2.8M (+$1.13M)
9% more funds holding
Funds holding: 22 → 24 (+2)
2.83% more ownership
Funds ownership: 20.64% → 23.47% (+2.8%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
+$443K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$30.1K |
| 3 |
FAM
Formidable Asset Management
Cincinnati,
Ohio
|
+$22.4K |
| 4 |
Jane Street
New York
|
+$18.3K |
| 5 |
LPL Financial
San Diego,
California
|
+$12.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$40.7K |
| 2 |
LNWTC
Laird Norton Wetherby Trust Company
Seattle,
Washington
|
-$16.5K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$14.5K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$12.8K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$2.62K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TSS
26
Two Sigma Securities
New York
| – | -$14.5K | -13,180 | Closed |
|
|
27
Citadel Advisors
Miami,
Florida
| – | -$12.8K | -11,642 | Closed |
|
|
28
Bank of America
Charlotte,
North Carolina
| – | -$2.62K | -2,382 | Closed |
|
|
MC
29
Meteora Capital
Boca Raton,
Florida
| – | -$4 | -4 | Closed |
|
AEON Hedge Fund Activity: Q1 2026 in Review
24 of the 8,134 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q1 2026, worth a combined $2.8M — up 68% from $1.67M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new AEON positions and 5 closed out — a net gain of 4 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Dauntless Investment Group, adding an estimated $443K. The largest seller was XTX Topco, cutting an estimated $40.7K.
- 24 institutional investors held AEON Biopharma (AEON) as of Q1 2026, up from 22 in Q4 2025.
- Funds reported $2.8M of AEON Biopharma stock for Q1 2026, up 68% quarter-over-quarter.
- 9 funds opened new AEON Biopharma positions in Q1 2026 and 5 closed out, a net change of +4 holders.
- The largest AEON Biopharma buyer in Q1 2026 was Dauntless Investment Group, an estimated $443K added.
- The largest AEON Biopharma seller in Q1 2026 was XTX Topco, an estimated $40.7K sold.
Based on aggregated 13F filings for Q1 2026.